Intra-Cellular Therapies Aktie
122,00
EUR
+1,00
EUR
+0,83
%
131,89
USD
-0,02
USD
-0,02
%
Werbung
Intra-Cellular Therapies Aktie Analyse
08.02.18 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
15.12.17 | Intra-Cellular Therapies Buy | Canaccord Adams | |
16.12.16 | Intra-Cellular Therapies Overweight | Cantor Fitzgerald | |
29.09.16 | Intra-Cellular Therapies Neutral | SunTrust | |
29.09.16 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
17.09.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
14.04.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets |
Werbung
Werbung